DUBLIN, April 29, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Multinationals Threatening Domestic Growth of India's Generics Firms

Previously considered a thorn in the side of Big Pharma, the Indian generics industry is emerging as a key hunting ground for Multinational Corporations (MNCs) looking to extend their reach into emerging economies. Domestic players, however, may pay the price for the intrusion, states the latest report from research and consulting firm The authors.

The new report* - the first in the company's new PharmaSphere series - explains that while the Indian generics industry has witnessed significant growth over the last year, pharmaceutical giants, which are keen to leverage the nation's relatively low cost of production and high quality facilities, may slow the growth of India's domestic companies.

Adefemi Adenuga, analyst with the Industry Dynamics Team, says: Indian generics companies, particularly the smaller ones, do not possess the capabilities to match those of these larger players, and are therefore not able to enjoy the resultant scope and scale economies, which are two key requirements in the price-sensitive generics business.

Indeed, MNCs are actively positioning themselves to capture a significant portion of the Indian generics market, primarily through authorized generic versions of their off-patent blockbusters. Adenuga states: The branded generics offered by these large companies may appeal more to the brand-sensitive portion of the Indian population, which now numbers over 1.2 billion, especially if these products are sold at prices that compete well with unbranded pharmaceuticals.

The The authors analyst also believes that the future of the Indian generics market will be shaped by how its government reacts to the current pressure by MNCs regarding the nation's patent laws. Both Bayer and Novartis have launched strong challenges against India's compulsory licensing of key drugs over the last 12 months.

Although the government is currently standing its ground, increasing pressure from Big Pharma may force it to relax some of its more stringent laws to favor foreign companies, considering the economic implications of their presence in the country.

This will come as a blow to domestic generics manufacturers, who often reap the benefits of compulsory licenses and legal rulings against foreign multinationals.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Generics Industry Dynamics
3.1 Generics to the Fore

4 Strategic Deals Trends
4.1 Big Pharma's need to plug its revenue gap
4.2 Governments cut healthcare spending as financial austerity spreads globally
4.3 Low margins in the generics business necessitate scale economies
4.4 Highlighted Deals from 2012

5 Generics in North America
5.2.1 The US Pharmaceutical Industry

6 Generics in the Asia-Pacific (APAC)
6.1 Overview
6.2 Australia: Healthcare Policy Reform and the Generics Business
6.3 Japan

7 Generics in Europe and Africa
7.1 Overview
7.2 Europe
7.3 Africa

8 Generics in the BRIC Countries
8.1 Overview
8.2 Brazil
8.3 Russia
8.4 India
8.5 China

9 Strategic Outlook
9.1 Patent expiries and evolution of the regulatory landscape fuel generics

10 Appendix

Companies Mentioned

- Actavis
- FDA
- Merck
- Mylan Pharmaceuticals
- Pfizer
- PhRMA
- Supera Farma Laboratórios
- Watson

For more information visit "PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013"

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets